This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
AngioDynamics (ANGO) Q4 Performance Dull, Competition Rife
by Zacks Equity Research
AngioDynamics' (ANGO) fourth-quarter performance dull; stiff competition a serious concern.
AngioDynamics (ANGO) Misses Q4 Earnings & Revenue Estimates
by Zacks Equity Research
AngioDynamics (ANGO) misses Q4 earnings and revenue estimates; international sales high.
AngioDynamics (ANGO) Misses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
AngioDynamics (ANGO) delivered earnings and revenue surprises of -4.76% and -0.75%, respectively, for the quarter ended May 2018. Do the numbers hold clues to what lies ahead for the stock?
Q2 Earnings Season In Focus
by Zacks Equity Research
Q2 Earnings Season In Focus
What's Sparking Market Futures? Big Q2 Results
by Mark Vickery
There is a bright, shining beacon markets appear to be attracted to currently: Q2 earnings season.
What's in Store for AngioDynamics (ANGO) in Q4 Earnings?
by Zacks Equity Research
AngioDynamics' (ANGO) expanding product pipeline, international market expansion and cost-saving initiatives to provide growth opportunities in Q4.
Why Is AngioDynamics (ANGO) Up 13.9% Since Its Last Earnings Report?
by Zacks Equity Research
AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
AngioDynamics (ANGO) Product Line Strong, Debt Level High
by Zacks Equity Research
AngioDynamics (ANGO) rides on promising NanoKnife performance. Dwindling sales are a concern.
AngioDynamics (ANGO) Beats on Q3 Earnings, Reiterates View
by Zacks Equity Research
AngioDynamics (ANGO) witnesses gross margin expansion and strong profits in the third quarter of fiscal 2018. However, lower sales in the company's RFA product line in Japan is a concern.
AngioDynamics Receives FDA Nod, to Treat Pancreatic Cancer
by Zacks Equity Research
AngioDynamics (ANGO) gets flagship NanoKnife designated with EAP.
AngioDynamics (ANGO) Banks on Buyouts, Debt Level High
by Zacks Equity Research
AngioDynamics (ANGO) continues to expand its business on the back of acquisitions and strategic alliances.
Zacks.com featured highlights include: AngioDynamics, Zumiez, GP Strategies, AngloGold and Raymond James
by Zacks Equity Research
Zacks.com featured highlights include: AngioDynamics, Zumiez, GP Strategies, AngloGold and Raymond James
Bet on These 5 PEG-Ratio Based GARP Picks
by Zacks Equity Research
A lower PEG ratio, preferably less than one, is always better for GARP investors.
AngioDynamics (ANGO) Misses on Earnings, Revenues in Q2
by Zacks Equity Research
Dwindling revenues in two major segments hurt AngioDynamics' (ANGO) second-quarter results.
Can AngioDynamics (ANGO) Pull a Surprise in Q2 Earnings?
by Zacks Equity Research
AngioDynamics (ANGO) to gain from solid product portfolio and demand for Solero MTA system. However, unfavorable estimates are a concern.
Why Is AngioDynamics (ANGO) Up 5.3% Since the Last Earnings Report?
by Zacks Equity Research
AngioDynamics (ANGO) reported earnings more than a month ago. What's next for the stock? We take a look at earnings estimates for some clues.
AngioDynamicis' (ANGO) Solero MTA System to Drive Growth
by Zacks Equity Research
Growth in the core Angiographic Catheter business is also likely to fortify the company's footprint in the global space.
AngioDynamics (ANGO) Misses on Earnings & Revenues in Q1
by Zacks Equity Research
AngioDynamics' (ANGO) adjusted gross margin decreased year over year owing to voluntary market withdrawal of the Acculis Microwave Tissue Ablation System.
Can AngioDynamics (ANGO) Spring a Surprise in Q1 Earnings?
by Zacks Equity Research
AngioDynamics (ANGO) is set to report first-quarter fiscal 2018 (ending Aug 31, 2017) results on Sep 28.
AngioDynamics' BioFlo Platform Strong, Debt Levels High
by Zacks Equity Research
AngioDynamics' (ANGO) exclusive Endexo technology in the BioFlo unit is expected to enhance the company's growth trajectory. However, high debt levels limit the company's core business strategies.
AngioDynamics (ANGO) Up 10.8% Since Earnings Report: Can It Continue?
by Zacks Equity Research
AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
AngioDynamics (ANGO) Shares Down Despite Q4 Earnings Beat
by Zacks Equity Research
AngioDynamics (ANGO) revenues declined year over year in the fourth quarter. Recall of the Acculis product line under the oncology segment is also a concern.
AngioDynamics (ANGO) Down 11.7% Since Earnings Report: Can It Rebound?
by Zacks Equity Research
AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
AngioDynamics (ANGO) Prices 2.5M Secondary Share Offering
by Zacks Equity Research
AngioDynamics, Inc. (ANGO) announced that it has priced its underwritten public offering of 2.35 million shares of common stock.
5 Cheap Value Stocks to Tame a Capricious Market in Q2
by Zacks Equity Research
Given the volatile backdrop in the U.S. investment markets, we take a look at five companies which are great value bargains and poised for stellar gains in the second quarter that has just begun.